Oncolytics Biotech Inc T.ONC

Merck & Moderna combine Keytruda + personalized mRNA vaccine

[Noteable]

December 13, 2022 - "Personalized cancer vaccines are designed to prime the immune system so that a patient can generate a tailored antitumor response specific to their tumor mutation signature. mRNA-4157/V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor."

"The results of this randomized Phase 2b trial are exciting for the field. These data provide the first evidence that we can improve on the rates of recurrence-free survival achieved by PD-1 blockade in resected high-risk melanoma. These findings also provide the first randomized evidence that a personalized neoantigen approach may be beneficial in melanoma," said Jeffrey S. Weber, MD, PhD, principal investigator of the study and Deputy Director of the Perlmutter Cancer Center at NYU Langone. Dr. Weber is a paid consultant for Merck and Moderna.

"The Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection. Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% (HR=0.56 [95% CI, 0.31-1.08]; one-sided p-value=0.0266) compared with KEYTRUDA alone."

https://www.biospace.com/article/releases/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-r-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-942-trial/

[ Moderna's personalized vaccine is a bespoke mRNA cancer vaccine that is made to address a patient's specific needs in an individualized fashion using a personalized neoantigen approach which does not have application to a broad set of patients with a specific cance type like ONCY's pelareorep is able to accomplish ]

[Quentin30]

It doesn't need to be off the shelf, if tailored manufacturing can rapidly create that personalised treatment. You're losing it Noteable. When personalised CAR-T therapies are available en masse, then it's a paradignm shift in treatment, and ONCY will only have had a year or two to shine... so WHO is going to buy us out..?

[Lesalpes29]

Quentin we needed an other basher here. H.... HAPPY to see you back!

[Noteable]

Any personalized treatment has a limited market of ONE !!  ... whereas Big Pharma is seeking acquisition targets that have a broad application rather than one that has a limited market ... ERGO Big Pharma's interest in developing allogenic versus autologous CAR-T therapy. Moderna is developing an autologous vaccine therapeutic that is personalized. Unfortunately those bad actors like

[SundayMovies]

Your brain, Unnoteworthy, is autozeroIQlogous. 

[Lesalpes29]

Manipulation is here to stay until... 700 shares to push the SP from 2.40 to 2.34! Hold your shares until...

[Noteable]

A personalized therapy cannot be scaled to meet the larger market and therefore has a limited market of one - "one-at-a-time in a defined population of patients".

[Noteable]

In the Phase IIb KEYNOTE-942 trial, patients treated with Moderna's mRNA-4157/V940 vaccine plus Merck’s Keytruda (pembrolizumab) saw a 44% reduction in the risk of recurrence or death, as compared to those given Keytruda alone. This effect proved to be statistically significant, with a p-value of 0.0266.  Based on these data, the powerhouse partners plan to engage regulatory authorities